We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead has dominated the HCV drug market for years with unshakeable “absolute supremacy” since its new direct-acting antiviral (DAA) Sovaldi entered the market in December 2013.